DPYD IVS14+1G>A and 2846A>T Genotyping for the Prediction of Severe Fluoropyrimidine-Related Toxicity: A Meta-Analysis

• Lamont EB , SchilskyRL. The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res.5(9) , 2289–2296 (1999).
   PubMed Web of Science ®Google Scholar
• Walko CM , LindleyC. Capecitabine: a review. Clin. Ther.27(1) , 23–44 (2005).
   PubMed Web of Science ®Google Scholar
• Chau I , NormanAR, CunninghamD et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol.16(4) , 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Malet-Martino M , MartinoR. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist7(4) , 288–323 (2002).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB . Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that‘s the question. Cancer Invest.24(2) , 215–217 (2006).
   PubMed Web of Science ®Google Scholar
• Amstutz U , FroehlichTK, LargiadèrCR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics12(9) , 1321–1336 (2011).
   PubMed Web of Science ®Google Scholar
• Vreken P , van Kuilenburg AB, Meinsma R et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J. Inherit. Metab. Dis.19(5) , 645–654 (1996).
   PubMed Web of Science ®Google Scholar
• Wei X , McLeodHL, McMurroughJ et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest.98(3) , 610–615 (1996).
   PubMed Web of Science ®Google Scholar
• Morel A , Boisdron-CelleM, FeyL et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther.5(11) , 2895–2904 (2006).
   PubMed Web of Science ®Google Scholar
• Boisdron-Celle M , RemaudG, TraoreS et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett.249(2) , 271–282 (2007).
   PubMed Web of Science ®Google Scholar
• Schwab M , ZangerUM, MarxC et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol.26(13) , 2131–2138 (2008).
   PubMed Web of Science ®Google Scholar
• Braun MS , RichmanSD, ThompsonL et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol.27(33) , 5519–5528 (2009).
   PubMed Web of Science ®Google Scholar
• Amstutz U , FareseS, AebiS, LargiadèrCR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics10(6) , 931–944 (2009).
   PubMed Web of Science ®Google Scholar
• Gross E , BusseB, RiemenschneiderM et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One3(12) , e4003 (2008).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , MeinsmaR, ZoetekouwL, van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics12(7) , 555–558 (2002).
   PubMedGoogle Scholar
• Salgueiro N , VeigaI, FragosoM et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet. Med.6(2) , 102–107 (2004).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , HaasjesJ, RichelDJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res.6(12) , 4705–4712 (2000).
   PubMed Web of Science ®Google Scholar
• Mattison L , JohnsonMR, DiasioR. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics12(2) , 133–144 (2002).
   PubMedGoogle Scholar
• Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J. Clin. Oncol.16(11) , 3537–3541 (1998).
   PubMed Web of Science ®Google Scholar
• Chansky K , BenedettiJ, MacDonaldJS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer103(6) , 1165–1171 (2005).
   PubMed Web of Science ®Google Scholar
• Little J , HigginsJP, IoannidisJP et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE statement. Ann. Intern. Med.150(3) , 206–215 (2009).
   PubMed Web of Science ®Google Scholar
• DerSimonian R , LairdN. Meta-analysis in clinical trials. Control. Clin. Trials7(3) , 177–188 (1986).
   PubMedGoogle Scholar
• Zintzaras E , LauJ. Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J. Clin. Epidemiol.61(7) , 634–645 (2008).
   PubMed Web of Science ®Google Scholar
• Lau J , IoannidisJP, SchmidCH. Quantitative synthesis in systematic reviews. Ann. Intern. Med.127(9) , 820–826 (1997).
   PubMed Web of Science ®Google Scholar
• Egger M , Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ315(7109) , 629–634 (1997).
   PubMed Web of Science ®Google Scholar
• Harbord RM , EggerM, SterneJA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med.25(20) , 3443–3457 (2006).
   PubMed Web of Science ®Google Scholar
• Begg CB , MazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics50(4) , 1088–1101 (1994).
   PubMed Web of Science ®Google Scholar
• Largillier R , Etienne-GrimaldiMC, FormentoJL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res.12(18) , 5496–5502 (2006).
   PubMed Web of Science ®Google Scholar
• Sulzyc-Bielicka V , Bińczak-KuletaA, PiochW et al. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol. Rep.60(2) , 238–242 (2008).
   PubMed Web of Science ®Google Scholar
• Kleibl Z , FidlerovaJ, KleiblovaP et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma56(4) , 303–316 (2009).
   PubMed Web of Science ®Google Scholar
• Boige V , MendiboureJ, PignonJP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol.28(15) , 2556–2564 (2010).
   PubMed Web of Science ®Google Scholar
• Kristensen MH , PedersenPL, MelsenGV, EllehaugeJ, MejerJ. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J. Int. Med. Res.38(3) , 870–883 (2010).
   PubMed Web of Science ®Google Scholar
• Cerić T , ObralićN, Kapur-PojskićL et al. Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-fluorouracil and capecitabine. Bosn. J. Basic Med. Sci.10(2) , 133–139 (2010).
   PubMed Web of Science ®Google Scholar
• Cellier P , LeducB, MartinL et al. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer11 , 98 (2011).
   PubMedGoogle Scholar
• Deenen MJ , TolJ, BuryloAM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res.17(10) , 3455–3468 (2011).
   PubMed Web of Science ®Google Scholar
• Cho HJ , ParkYS, KangWK, KimJW, LeeSY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther. Drug. Monit.29(2) , 190–196 (2007).
   PubMed Web of Science ®Google Scholar
• Maekawa K , SaekiM, SaitoY et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J. Hum. Genet.52(10) , 804–819 (2007).
   PubMed Web of Science ®Google Scholar
• Sutton AJ , CooperNJ, LambertPC, JonesDR, AbramsKR, SweetingMJ. Meta-analysis of rare and adverse event data. Expert Rev. Pharmacoecon. Outcomes Res.2(4) , 367–379 (2002).
   PubMedGoogle Scholar
• Swen JJ , NijenhuisM, de Boer A et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin. Pharmacol. Ther.89(5) , 662–673 (2011).
   PubMed Web of Science ®Google Scholar
• Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J. Clin. Oncol.16(11) , 3537–3541 (1998).
   PubMed Web of Science ®Google Scholar
• Ezzeldin H , JohnsonMR, OkamotoY, DiasioR. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res.9(8) , 3021–3028 (2003).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , DobritzschD, MeinsmaR et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem. J.364(Pt 1) , 157–163 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson MR , WangK, DiasioRB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res.8(3) , 768–774 (2002).
   PubMed Web of Science ®Google Scholar
• Loganayagam A , Arenas-HernandezM, FairbanksL, RossP, SandersonJD, MarinakiAM. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother. Pharmacol.65(2) , 403–406 (2010).
   PubMed Web of Science ®Google Scholar
• Ezzeldin HH , LeeAM, MattisonLK, DiasioRB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res.11(24 Pt 1) , 8699–8705 (2005).
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES , EtienneMC, MilanoG, McLeodHL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics10(3) , 217–223 (2000).
   PubMedGoogle Scholar
• Savva-Bordalo J , Ramalho-CarvalhoJ, PinheiroM et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer10 , 470 (2010).
   PubMed Web of Science ®Google Scholar
• Amstutz U , FareseS, AebiS, LargiadèrCR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J. Exp. Clin. Cancer Res.27(1) , 54 (2008).
   PubMedGoogle Scholar
• Ticha I , KleiblovaP, FidlerovaJ, NovotnyJ, PohlreichP, KleiblZ. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother. Pharmacol.64(3) , 615–618 (2009).
   PubMed Web of Science ®Google Scholar
• Paré L , PaezD, SalazarJ et al. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br. J. Clin. Pharmacol.70(2) , 268–272 (2010).
   PubMed Web of Science ®Google Scholar
• Mercier C , CiccoliniJ. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin. Colorectal Cancer6(4) , 288–296 (2006).
   PubMed Web of Science ®Google Scholar
• van Staveren MC , Theeuwes-OonkB, GuchelaarHJ, van Kuilenburg AB, Maring JG. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother. Pharmacol.68(6) , 1611–1617 (2011).
   PubMed Web of Science ®Google Scholar
• Ciccolini J , GrossE, DahanL, LacarelleB, MercierC. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer9(4) , 224–228 (2010).
   PubMed Web of Science ®Google Scholar
• Jennings BA , KwokCS, WillisG, MatthewsV, WawruchP, LokeYK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet. Genomics22(4) , 290–304 (2012).
   PubMed Web of Science ®Google Scholar
• Afzal S , GusellaM, VainerB et al. Combinations of polymorphisms in genes involved in the 5-fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin. Cancer Res.17(11) , 3822–3829 (2011).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Little J, Higgins JP (Eds). The HuGENet™ HuGE Review Handbook, Version 1.0. Ottawa, Ontario, Canada: HuGENet Canada Coordinating Centre (2006). www.medicine.uottawa.ca/public-health-genomics/web/assets/documents/HuGE_Review_Handbook_V1_0.pdf (Accessed 12July2012)
   Google Scholar
• Open Meta-Analyst. http://tuftscaes.org/open_meta
   Google Scholar